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Abstract
Background:  The expression of the human Eag1 potassium channel (Kv10.1) is normally
restricted to the adult brain, but it has been detected in both tumour cell lines and primary
tumours. Our purpose was to determine the frequency of expression of Eag1 in soft tissue sarcoma
and its potential clinical implications.
Results: We used specific monoclonal antibodies to determine the expression levels of Eag1 in
soft tissue sarcomas from 210 patients by immunohistochemistry. Eag1 was expressed in 71% of all
tumours, with frequencies ranging from 56% (liposarcoma) to 82% (rhabdomyosarcoma). We
detected differences in expression levels depending on the histological type, but no association was
seen between expression of this protein and sex, age, grade or tumour size. Four cell lines derived
from relevant sarcoma histological types (fibrosarcoma and rhabdomyosarcoma) were tested for
Eag1 expression by real-time RT-PCR. We found all four lines to be positive for Eag1. In these cell
lines, blockage of Eag1 by RNA interference led to a decrease in proliferation.
Conclusion: Eag1 is aberrantly expressed in over 70% sarcomas. In sarcoma cell lines, inhibition
of Eag1 expression and/or function leads to reduced proliferation. The high frequency of
expression of Eag1 in primary tumours and the restriction of normal expression of the channel to
the brain, suggests the application of this protein for diagnostic or therapeutic purposes.
Background
Ion channels play important roles in several cellular func-
tions such as excitability, contraction, cell cycle progres-
sion and metabolism [1]. The link between ion channels
and disease has received widespread attention in the last
decade as mutations in several ion channels have been
shown to be responsible for certain neurological disorders
[2,3]. Whereas many of these mutations affect well-char-
acterised channels of the nervous system, little is know
about the effects in non-excitable cells. The voltage-acti-
vated potassium channel ether à go-go (Eag1) has recently
gained increased interest because of its potential onco-
genic role [4,5]. We and others [4] have shown that the
Eag1 channel is involved in cell-cycle progression of
tumour cells, and that a significant reduction in the cell
proliferation of these cell lines could be achieved by
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inhibiting Eag1 expression using antisense oligonucle-
otides. It has also been reported that expression of this
channel in Chinese hamster ovary cells (CHO) increased
both metabolic activity and proliferation rate. In an
immunodeficient mouse model, Eag1-transfected CHO
cells caused rapidly growing tumours, while wild type
CHO cells were much less aggressive, suggesting that Eag1
expression confers a selective advantage to cancer cells [4].
Recently, functional expression of Eag1 was found in sam-
ples of cervix carcinoma from patients, while the channel
was absent in normal tissue [5].
Another example of the relationship of Eag1 with the cell
cycle is the expression of the channel in myoblasts, but
not in adult human skeletal muscle. This suggests that
Eag1 expression is a cell-cycle related phenomenon, since
myoblast fusion is intimately coupled to irreversible cell
cycle arrest [6]. Together, these data point to a direct
involvement of Eag1 channels in cell proliferation and
suggest that these channels participate in the transforma-
tion of normal cells into tumour cells. Because of their
oncogenic properties, their restricted distribution in nor-
mal tissue and ubiquitous expression in tumour cells
[4,7], Eag1 potassium channels have gained recent inter-
est as potential targets for cancer detection and therapy.
Soft tissue sarcomas are relatively rare (less than 1% of all
cancers) and represent a highly heterogeneous group of
tumours. More than 40% of new sarcoma patients die
from the disease each year [8]. The relatively small
number of cases and great diversity in histopathologic
presentation, anatomic site and biological behaviour has
made a comprehensive understanding of these disease
entities extremely difficult. Clinicians and patients are still
faced with limited options of chemotherapy, surgery and
radiation therapy, with only modest improvement in sur-
vival and cure. While surgery and radiation therapy can be
effective in soft tissue sarcomas that manifest a more
regional biology, sarcomas with a more systemic biology
benefit little from the currently available therapeutic
tools. In the present work we studied the expression of
Eag1 in soft tissue sarcomas of patients because the nor-
mal cells that give rise to these tumours do not express the
Eag1 channel [4,6].
Results
Efficiency of Eag1 detection depends on the duration of 
storage
Samples from 210 patients with soft tissue sarcoma were
stained for Eag1 expression, from which positive signals
were observed with high frequency. Eag1 immuno-reac-
tivity was preferentially cytoplasmic with predominant
perinuclear localization consistent with results reported
by others [9]. Figure 1 shows examples of the different
intensities of Eag1 staining leading to the classifications
(0, 1+, 2+ and 3+) used for the analysis. The staining
intensity for the channel was homogeneous within a prep-
aration and clearly predominant in tumour cells as com-
pared to neighbouring morphologically non-malignant
cells (Fig. 1 and Fig. 3).
When analysing the frequency of positive Eag1 signals, we
noticed a correlation between how recently the sample
had been obtained and the frequency of positive cases.
Figure 2 (insert) shows the distribution of Eag1-expressing
tumours as a function of the year (between 1997 and
2004) in which the sample had been originally obtained.
Most of the cases stemming from 1997 to 1999 were neg-
ative, while 50% of cases from 2000 onwards were posi-
tive. The limited number of cases from 2002 precludes
statistical analysis, but 70% of tumours dating from both
2003 and 2004 were positive. There is an inverse correla-
tion between the time elapsed between storage of the sam-
ple and the performance of immunohistochemistry (Fig.
2). Samples archived for up to two years have a homoge-
neous positive rate for Eag1 and there is no statistically
significant difference between samples stored for one or
two years. Samples older than three years showed a
decrease in positive signals for Eag1, with 22% of positive
cases in six-year old samples. This strongly suggests that
the Eag1 antigen is labile and becomes undetectable with
time. We cannot exclude that the storage conditions could
influence antigen stability, and further studies will be
required to clarify under which conditions the Eag1 anti-
gen becomes unstable. This particular feature of the Eag1
protein impairs retrospective studies and reduces the
effective availability of samples.
Eag1 is frequently expressed in soft tissue sarcomas
Due to the aforementioned limitations, we used only
recently obtained samples for analysis. We stained sam-
ples from resective surgical interventions not older than
one year (from 2003 and 2004). This limited our collec-
tion to 121 samples from 119 sarcoma patients. Table 1
summarises the clinico-pathological features of the cases
and the Eag1 channel expression. The frequency of expres-
sion of Eag1 in soft tissue sarcoma averaged 71% of the
cases studied, with variations between histological types
from 56% (liposarcoma) to 82% (rhabdomyosarcoma).
No association was detected between Eag1 expression and
sex, age, site, grade or tumour size. The expression of Eag1
in the primary site or in metastases (75 and 85%, respec-
tively) was higher than in recidivating tumours (56%),
but this difference was not statistically significant. Figure
3 shows representative images of normal (morphologi-
cally non-malignant) and neoplastic tissue from all six
subtypes of soft tissue sarcoma studied here. We also
stained normal tissue from the same patients, which were
negative for Eag1 in most of the cases except for restricted
populations of normal cells [9].Molecular Cancer 2006, 5:42 http://www.molecular-cancer.com/content/5/1/42
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In the attempt to quantify Eag1 staining, we used a simpli-
fied adaptation of the HER2 score routinely applied to
breast cancers (HercepTest), where the samples are classi-
fied as 0, 1+, 2+ and 3+ depending on the number of cells
stained and the intensity of staining per cell. We consid-
ered staining intensities of 1+ as low Eag1 expression and
2–3+ as high Eag1 expression (Fig. 1). Analysing tumours
using this score system, we found high Eag1 expression in
57 patients (47% of the total population), while the other
29 cases showed low Eag1 expression (Table 2). Neither of
these two groups showed a correlation between Eag1
expression and sex, grade, site or tumour size, but we
observed differences between histological types (Table 2).
Rhabdomyosarcoma and synovial sarcoma frequently
showed high Eag1 levels (100% and 88% of the tumours
(p < 0.01), respectively), while other histological types
had homogeneous distribution between low and high
Eag1 expression.
Reduction of Eag1 promotes inhibition of proliferation in 
soft tissue sarcoma cell lines
To establish a useful model for further studies, we tested
Eag1 expression in several well-established sarcoma cell
lines (rhabdomyosarcoma – TE-671, A-204 and fibrosar-
coma – HT-1080, Hs633t). As positive control we used
CHO cells transfected with an Eag1 pTracer vector con-
struct and cells transfected with empty vector as a negative
control. These negative control cells did not show Eag1
expression as determined by electrophysiology or immu-
nocytochemistry [4] and contained very low Eag1 mRNA
concentration (less than 0.3 copies/1000 cells) in real-
time PCR experiments. The positive control (expressing
Typical staining of tumour samples with a single-chain antibody against Eag1 Figure 1
Typical staining of tumour samples with a single-chain antibody against Eag1. Eag1 shows homogeneous cytoplas-
mic staining with perinuclear localization. Shown are representative examples for the different intensities of Eag1 staining lead-
ing to the scoring of 0 (A, morphologically non-malignant skeletal muscle from a rhabdomyosarcoma case), 1+ (B, malignant 
fibrous histiocytoma), 2+ (C, leiomyosarcoma) and 3+ (D, rhabdomyosarcoma) used for further analysis. Magnification: 20×.Molecular Cancer 2006, 5:42 http://www.molecular-cancer.com/content/5/1/42
Page 4 of 10
(page number not for citation purposes)
Eag1 under the control of the CMV promoter) showed
39,000 copies per 1000 cells. Such values were of course
not reached by any of the tested sarcoma cell lines, but all
four lines were clearly positive, with over 140 copies/1000
cells (Table 3).
It has been reported that lowering Eag1 expression in
tumour cell lines leads to a reduction of cell proliferation,
indicating that Eag1 offers a selective advantage for
tumour cells [4]. Therefore, blockage of Eag1 could lead to
a reduction of sarcoma cell proliferation, as has been
described for melanoma cells [10,11]. Imipramine blocks
Eag1 (among other channels) with relative high affinity
[12] and we thus studied its effects on the proliferation of
the Eag1-positive sarcoma cell lines. We observed a clear
reduction of proliferation in all cells incubated in the
presence of 10 µM imipramine for 4 days, which is com-
patible with the hypothesis that Eag1 participates in the
proliferation of these cell types (Fig. 4).
Because imipramine is rather non-specific, we used RNA
interference as a more specific tool to test if Eag1 partici-
pates in the proliferation of soft tissue sarcoma cell lines.
We have previously reported the optimization of siRNAs
against Eag1 [13]. The reduction of Eag1 mRNA levels by
siRNA varies from 70 to 82% depending on the cell line
[13]. Figure 4 shows the inhibition of cell proliferation
induced by transfection with siRNA in each cell line. As a
positive control we used siRNA against GAPDH, which
induces a reduction in cell proliferation (or cell metabo-
lism). As a negative control we included a scrambled
siRNA. The metabolic activity data were normalized by
the values obtained in the presence of the transfection rea-
gent. A significant reduction of proliferation can be
Preservation of Eag1 antigen in paraffin-embedded tissue Figure 2
Preservation of Eag1 antigen in paraffin-embedded tissue. The percentage of Eag1-expressing tumours decreases with 
the elapsed storage time of samples before the immunohistochemistry procedure was performed. Insert: The percentage of 
Eag1-expressing tumours increases over the years (1997–2004) indicating that the Eag1 antigen is not stable in paraffin-embed-
ded tissue for long periods of time. The numbers indicate the number of cases tested for each data point. *p < 0.01, **p < 
0.001Molecular Cancer 2006, 5:42 http://www.molecular-cancer.com/content/5/1/42
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observed in all cells treated with siRNA for Eag1 (and for
GAPDH). Besides A-204 rhabdomyosarcoma cells, the
level of reduction of cell proliferation was the same for
both siRNA and imipramine, indicating a possible shared
mechanism – namely Eag1 inhibition.
Discussion
We report here that the voltage-gated potassium channel
Eag1 is frequently and robustly expressed in a large pro-
portion of human soft tissue sarcomas. Previous and
ongoing studies on this channel have demonstrated that it
is expressed in a very selective manner in the brain and a
few peripheral cell populations, all of which are epithelial
in origin. No expression of the channels has been detected
in connective tissues. However, we have found channel
expression in 70% of human soft tissue sarcomas and sev-
eral sarcoma cell lines, but this does not correlate with
epidemiological or pathological parameters of the
tumours, except for the histological type; rhabdomyosar-
coma and synovial sarcoma are strongly positive most fre-
quently.
Unfortunately, samples stored for periods of time longer
than two years give unreliable results, probably due to
antigen degradation during storage. The liability of the
antigen under the archival conditions is not unique for
Eag1. An apparent reduction in signal was observed for
oestrogen receptor in ten breast cancer samples that were
re-evaluated four years after the first analysis (data not
shown). These findings imply that archival samples have
to be used cautiously when testing potential clinical corre-
lations of a particular antigen. In the case of Eag1, this pre-
cludes retrospective studies spanning periods longer than
two years. We have nevertheless initiated the prospective
analysis of our cases. Despite the limited time period (and
number of cases), we have found that the tumours from
patients who died over the two-year follow up period were
much more likely to express significant levels of Eag1. Of
the 19 registered deaths, tumours from 17 expressed Eag1
highly. We could not extract much information from his-
tological samples such as rhabdomyosarcoma or synovi-
osarcoma because of their generally high Eag1 expression
levels (29% and 17% mortality, respectively, all these
cases showed high Eag1 expression). Nevertheless, a
detailed analysis of the outcome in the liposarcoma pop-
ulation suggests the association of high Eag1 expression
with a bad prognosis. Of the 32 liposarcoma cases, 6
(19%) had died during the two-year follow-up period and
Representative images of normal and tumour tissue Figure 3
Representative images of normal and tumour tissue. Alkaline phosphatase staining using anti-Eag1 antibody. Examples 
of fibrosarcoma (A, G), leimyosarcoma (B, H), liposarcoma (C, I), malignant fibrous histiocytoma (D, J), rhabdomyosarcoma (E, 
K) and synovial sarcoma (F, L). In all cases staining of Eag1 was restricted to tumours cells in comparison with the surrounding 
normal tissue. Magnification: 10× (A-F), 40× (G-L)Molecular Cancer 2006, 5:42 http://www.molecular-cancer.com/content/5/1/42
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5 of these were high Eag1 expressing tumours. These fatal-
ities correspond to 38% of the total high Eag1 expressing
liposarcomas, while 93% of the patients with Eag1 nega-
tive tumours survived the follow-up period. We also
found an indication that the frequency of recurrent dis-
ease was higher in the Eag1 positive population- the inci-
dence of recurrence (13%) in Eag1 positive cases was
twice as great as that of the Eag1 negatives (6%). Taken
together, our data may indicate an association between
Eag1 expression and bad prognosis. Further studies with a
longer outcome (5 years) and a higher number of patients
will clarify the potential usefulness of Eag1 as a prognostic
marker.
Due to the behaviour of the antigen with time, prospec-
tive studies will be required to investigate whether there is
any correlation between levels of Eag1 expression and
clinical outcome and/or response to therapy. Such a cor-
relation would obviously be of great interest, since the
channel could then serve as a prognostic marker. The lack
of correlation of the channel with epidemiological factors
(sex, age, grade and site of tumour) makes it difficult to
assess a potential prognostic value of Eag1 expression at
this stage. However, it should be kept in mind that the his-
topathological samples showing the highest abundance of
Eag1 expression, rhabdomyosarcoma and synovial sar-
coma (p < 0.01), are particularly aggressive tumours.
There was also a clear difference between tumour and
morphologically non-malignant tissue in the same slides
with respect to Eag1 expression, the non-malignant tissue
always being negative. This could open the possibility of
the use of Eag1 as a tool for the differential diagnosis of
malignant transformation together with morphological
criteria.
It is still remains possible that the frequency of negative
tumours (29%) in our series is due to poor detection sen-
sitivity of the antibody and that the actual incidence of
Eag1 expression is even higher. Our Eag1 detection proce-
dure relied on a directly coupled single chain antibody.
This reduces the probability of false positives that can
arise with the use of secondary antibodies and developing
systems, but simultaneously looses two multiplicative
amplification steps – the secondary antibody and the
widely used peroxides polymers. Therefore, while our
method is more specific, it is about 60 times less sensitive
than other conventional immunohistochemical proce-
dures. The application of methods specifically designed to
detect minute quantities of biological macromolecules
such as in-situ immuno-PCR [14] will give a clearer esti-
mate of the actual incidence of Eag1 over-expression in
soft tissue sarcomas. Another factor increasing the diffi-
culty of analysing Eag1 expression, and more specifically
its potential usefulness as a tumour marker, is that Eag1
immunoreactivity is mainly intracellular (Figure 1).
Although electrophysiological experiments detected Eag1
currents in tumour cells [5,7], unequivocally indicating
surface expression of functional channel proteins, the vast
majority of the protein in a particular cell is intracellular.
Even the artificially expressing cell line used in this study
shows mainly cytoplasmic Eag1 staining, while exhibiting
robust Eag1 currents in electrophysiological experiments.
We therefore cannot exclude a correlation between
plasma membrane Eag1 and clinical outcome.
Table 2: Tumour histology and dichotomised hEAG1 expression.
Low Eag1 (%) High Eag1 (%)
Histology
Fibrosarcoma 4 (50%) 4 (50%)
Leiomyosarcoma 9 (48%) 10 (52%)
Liposarcoma 5 (28%) 13 (72%)
Malignant fibrous histiocytoma 10 (56%) 8 (44%)
Rhabdomyosarcoma 0 (0%) 14 (100%)
Synovial sarcoma 1 (12%) 8 (88%)
Total 29 (27%) 57 (73%)






Male 54 (45%) 35 (65%)
Female 67 (55%) 51 (76%)
Age (years)
< 14 11 (9%) 9 (82%)
15 – 34 19 (16%) 14 (74%)
35 – 64 65 (54%) 46 (71%)
> 65 26 (21%) 17 (65%)
Histology
Fibrosarcoma 12 (10%) 8 (67%)
Leiomyosarcoma 26 (22%) 19 (73%)
Liposarcoma 32 (26%) 18 (56%)
Malignant fibrous histiocytoma 22 (18%) 18 (81%)
Rhabdomyosarcoma 17 (14%) 14 (82%)
Synovial sarcoma 12 (10%) 9 (75%)
Grade
Low 70 (58%) 49 (70%)
Moderate 23 (19%) 15 (65%)
High 28 (23%) 21 (75%)
Size
< 5 cm 74 (61%) 52 (70%)
> 5 cm 47 (39%) 33 (70%)
Site
Primary 76 (63%) 57 (75%)
Recurrence 32 (26%) 18 (56%)
Metastasis 13 (11%) 11 (85%)
Total 121 86 (71%)Molecular Cancer 2006, 5:42 http://www.molecular-cancer.com/content/5/1/42
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Among the positive specimens, tumour cells and the sur-
rounding morphologically non-malignant cells can be
clearly demarcated. Should Eag1 consistently be a distinct
characteristic of tumour cells, this finding presents a
potential therapeutic opportunity to distinguish between
normal and tumour cells. If at least a fraction of the pro-
tein is accessible from the extracellular side, Eag1 may be
a good candidate for immunotherapeutical approaches.
In vitro experiments in this study showed that several sar-
coma cell lines express abundant Eag1 protein and that
blockage of the channel by imipramine correlates with a
reduction of cell proliferation. Unfortunately, the tricyclic
anti-depressant imipramine blocks not only Eag1 but also
many different channels such as cardiac and neuronal
sodium, calcium and potassium channels [12]. To over-
come this problem we used RNA interference, which rep-
resents a suitable alternative to functional blockers of
channel activity [13,15]. siRNAs for Eag1 have been thor-
oughly characterized and do not induce non-specific
responses [13]. Eag1 siRNA treatment resulted in a reduc-
tion of proliferation in all soft tissue sarcoma cell lines
(Fig. 4) to an extent comparable to that induced by imi-
pramine.
Conclusion
Although absent from healthy tissues, Eag1 expression
can be detected in 70% soft tissue sarcomas. The fre-
quency of Eag1 expression depends on the histological
type, but we found no association with other epidemio-
logical parameters. We could establish a preliminary asso-
ciation of high Eag1 expression and bad prognosis.
Additionally, we could show that inhibition of Eag1
expression and/or function reduces the proliferation of
several sarcoma cell lines. These findings highlight the
role of Eag1 in the proliferation of tumour cells and
prompt further studies to validate Eag1 as a potential diag-
nostic tool and/or anti-cancer ion channel target.
Methods
Patients
Two hundred and ten patients from the Brazilian National
Cancer Institute (INCA), who had surgery between 1997
and 2004 for resection of soft tissue sarcomas were
included in this study. The study was approved by the Eth-
ics Committee at INCA The clinical stage of the surgical
specimens was classified according to the three-grade sys-
tem [16], and the sarcomas were categorised on the basis
of histology and immunohistochemistry.
Anti-Eag1 antibody
A monoclonal antibody anti-Eag1, a fusion protein com-
prising the single chain antibody fragment derived against
the Eag1 potassium channel and bacterial alkaline phos-
phatase [9] was employed. The antibody was used at a
dilution of 1:100 in Tris buffered saline (TBS) with 0.2%
bovine serum albumin (BSA, Sigma Chemical Co., St
Louis, MO, USA) and 0.25% sodium azide.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue was cut into 4
µm sections and mounted on poly-L-lysine-coated slides.
Sections were deparaffinated in xylene and rehydrated in
descending alcohols. Antigen retrieval was performed by
heating the slides for 30 minutes in a steamer in 10 mM
citrate buffer solution pH 6.0. Afterwards, the slides were
cooled down to room temperature for at least 30 minutes.
Non-specific binding sites were blocked using 10% BSA in
TBS for 30 minutes at room temperature. Subsequently,
the slides were incubated for 2 hours at 37°C with the
antibody. Sections were rinsed with a detection buffer
solution containing in mM: 100 Tris-base, 100 NaCl and
5 MgCl2 at pH 8.8. Finally, sections were developed with
5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetra-
zolium (BCIP/NBT, Roche, Mannheim, Germany) for 20
minutes, slightly counterstained with nuclear fast red
(Dako, Glostrup, Denmark), dehydrated and mounted
with xylene-based balsam. Slides dating from 1997 until
2002 were stained in July – November 2003, whereas
slides prepared in 2003 and 2004 were stained in Novem-
ber – December of the respective year.
Immunohistochemical evaluation
To achieve a semi-quantitative estimation of expression
levels, we used an immunohistochemical score based on
the HercepTest for Her2/Neu [17]. Scores were 0 (less
than 10% of the tumour cells show staining), 1+ (faint
staining in more than 10% of the cells), 2+ (moderate
staining in more than 10% tumour cells) and 3+ (strong
Table 3: Eag1 expression at the RNA level
Origin Cell line hEag1a hEag2 hTFR
Rhabdomyosarcoma TE-671 373.1 ± 0.7 0.0004 ± 0.009 2997.5 ± 0.6
Rhabdomyosarcoma A-204 306 ± 0.6 0.0003 ± 0.01 2923.9 ± 0.7
Fibrosarcoma HT-1080 141.4 ± 0.5 65.2 ± 0.6 5891.5 ± 0.9
Fibrosarcoma Hs 633t 147.4 ± 0.9 74.7 ± 0.8 6255.7 ± 0.9
Epithelial CHO-pt 0.29 ± 0.8 0.0005 ± 0.001 -
Epithelial CHO-Eag1 39326 ± 0.8 0.0003 ± 0.001 -Molecular Cancer 2006, 5:42 http://www.molecular-cancer.com/content/5/1/42
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staining in more than 10% of the cells). The immunohis-
tochemical score was evaluated as negative (0), positive
(1) and strongly positive (2 and 3). Examples for each
score are shown in Figure 1.
Each stained slide was scored by two independent observ-
ers. There were no major disagreements regarding scoring
and the average scoring is reported.
Cell culture
Sarcoma-derived cell lines TE-671 (DSMZ ACC 263), HT-
1080 (DSMZ ACC315), and A-204 (DSMZ ACC 250)
were obtained from the DSMZ (Braunschweig, Germany).
Hs 633T (ECACC 89050201) was obtained from the
European Collection of Cell Culture (Salisbury, United
Kingdom). All cells were maintained in 125 ml flasks in a
humidified atmosphere at 37°C with 5% CO2 and pas-
saged every 4–5 days. TE-671, HT-1080 and Hs 633t cells
were cultured in Dulbecco's modified Eagle's medium
(DMEM, Invitrogen, Karlsruhe, Germany) and A-204 cells
were cultured in McCoy's 5A (Invitrogen) containing 10%
fetal calf serum (FCS).
siRNA transfections
Four different siRNAs were designed to target both Eag1
variants with accession numbers NM_172362 and
Inhibition of proliferation of sarcoma cell lines by imipramine or siRNAs Figure 4
Inhibition of proliferation of sarcoma cell lines by imipramine or siRNAs. Soft tissue sarcoma cells (rhabdomyosar-
coma – TE-671, A-204 and firbosarcoma – HT-1080, Hs633t) were transfected with siRNAs against Eag1 or were exposed to 
10 µM imipramine for 96 hours prior to performing the MTT assay. Data are relative values compared to proliferation in the 
presence of vehicle and presented as mean ± standard error. Statistical analysis compared imipramine with non-treated cells, 
and siRNA-Eag1 and -GAPDH against scrambled siRNA molecules, p values are shown.Molecular Cancer 2006, 5:42 http://www.molecular-cancer.com/content/5/1/42
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NM_172376, respectively, using the HiPerformance
siRNA Design Algorithm. siRNAs (25 nM) were trans-
fected using either Oligofectamine, Lipofectamine (Qia-
gen) or Dharmacon Transfection Reagent 2 (Dharmacon)
transfection reagents in OptiMEM medium (Invitrogen).
Cells were plated one day before transfection. The follow-
ing siRNAs were used: SiRNAs directed against hEag1
(KCNH1, Kv10.1) with the target sequence NM_172362:
Kv10.1 nt 1509–1529; Kv10.1-1 nt 236–256; Kv10.1-2 nt
863–883; Kv10.1-3 nt 1793–1813; Kv10.1-4 nt 1022–
1042. All siRNAs were synthesized by Qiagen and
annealed prior to use, except the commercial Negative
Control #1 and the human GAPDH siRNA (Ambion),
which we used as negative and positive controls, respec-
tively. The cells were incubated with the siRNA and the
transfection reagent for between 6 h and 8 h. Cells were
harvested for the experiments 96 hours after the start of
transfection. Additionally cells treated only with Opti-
MEM and Oligofectamine, Lipofectamine or Dharmacon
Transfection Reagent 2 were included as controls.
Real-Time RT PCR
Total RNA was purified from cultures using RNeasy mini
kit (Qiagen, Hilden, Germany) First strand cDNA was
produced using SuperScript (Invitrogen, Karlsruhe, Ger-
many) with gene-specific and oligo dT as primers. Real-
time PCR was performed on the template using the Taq-
Man system in an AbiPrism 7700 Sequence Detector
(Applied Biosystems, Foster City, CA). The oligonucle-
otides used have been described elsewhere [9]. The
human transferrin receptor was used as a control for RNA
integrity. The number of PCR cycles to reach detection
threshold was used to determine specific mRNA content
with a standard curve for interpolation.
Proliferation studies
Cell proliferation was determined by measuring the met-
abolic activity via reduction of the tetrazolium salt MTT
(3- [4,5-dimethylthiazol-2]-2,5-diphenyltetrazolium bro-
mide; Sigma, Munich, Germany). Cells were plated at a
density of 104 cells/ml and MTT (5 mg/ml) was added to
the cultures after 96 hours. Four hours later, the product
was solubilised and the reaction stopped using 10% SDS
in 0.01 M HCl. After overnight incubation, the colour was
read at 562 nm [18]. In some experiments, the actual
number of cells was measured in flow cytometry, giving
good correlation with the MTT method.
Statistical analysis
Statistical analysis was performed using the GraphPad
Prism® v.4.0 software Differences in sex, age, grade, size,
site and tumour histology were assessed using the Chi-
square test. We used one-way ANOVA test followed by
Bonferroni post test to compare differences that may have
arisen in the preservation of samples over the years. Addi-
tionally, the unpaired t test was used for the statistical
analysis of proliferation data.
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